Omeros (OMER) Tops Q4 Loss Per Share of 52c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Omeros (OMER) Tops Q4 Loss Per Share of 52c

Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results

March 7, 2016 5:22 PM EST

Conference Call Tomorrow, March 8, at 9:00 a.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2015, which include:

For 4Q 2015, sales revenues of OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% were $6.7 million, a 105% increase over 3Q, with OMIDRIA units shipped by wholesalers (sell-through)... More